

Contact:
PRISM BioLab Co., Ltd.
info@prismbiolab.com

26-1, Muraoka-Higashi 2-
chome. Fujisawa,
Kanagawa, JAPAN
www.prismbiolab.com



PRISM
BioLab

PRESS RELEASE

PRISM BioLab raised 1.3 billion yen in Series C funding

To discover drugs for incurable diseases with proprietary peptide mimetic technology

TOKYO, Japan, September 9, 2021: -- PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology "PepMetics™", today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. The Company aims to achieve further growth through pre-clinical studies and R&D of the pipeline.

Purpose of the fund-raising

PRISM will start pre-clinical study for the compound for the new targets developed using unique drug discovery platform. Also, PRISM will accelerate its R&D and strengthen corporate governance.

With this investment, PRISM will continue the development of its original peptide mimetic technology platform called 'PepMetics™', establishing new clinical pipelines in the fields of cancer and fibrosis, aiming to discover new drugs for various of intractable diseases.

Comments from investors

Hiroki Narita, President and CEO, DCI Partners Co., Ltd. (Lead Investor)

"We believe that PRISM BioLab's PepMetics™ is a highly promising technology that can modulate the targets that have been difficult with small molecules. We hope that this funding will further accelerate the research and development and lead to the discovery of innovative drugs.

Alain Parthoens, Managing Partner and Presentative Newton BioCapital Partners SPRL (Co-lead Investor)

"As the co-lead investor and a Belgium-based fund, we're very pleased to be supporting the innovative technologies emerging from Japan. PRISM's library comprises α -helix or β -turn mimicking compounds that can be tailored to disrupt interactions between intrinsically disorder proteins, an emerging class of targets in

various diseases including bladder cancer. Meanwhile, PRISM's recent deals with global pharmaceutical companies demonstrate the great potential with its unique approaches. With this new financing, we hope to support PRISM to become one of the leading companies in the drug discovery field.

Haruhiko Uchiyama, President & CEO, DBJ Capital Co., Ltd.

"Since our last investment, PRISM has made significant progress in both the pipeline and joint research with pharmaceutical companies using its platform technology and we made additional investments. We hope that the funds raised by this investment will further accelerate PRISM's research and development. We will continue to support PRISM."

Mitsuru Miyata, Representative Director, Healthcare Innovation Co., Ltd.

"PRISM has partnered with global pharma companies and the development of its two clinical pipelines are moving forward. We look forward to PRISM BIOLAB, with its unique peptide mimetic technology, as a pioneer in the medium-molecular drugs."

Ichiro Nagata, President & CEO, Gemseki Inc. (Shin Nihon Kagaku, Ltd. Corporate Venture Capital)

"In addition to our business development platform business, we also invest in startups with groundbreaking technologies. PRISM BioLab's proprietary platform technology has great potential to enable drug discovery for targets which were previously considered difficult to develop. We are confident that PRISM BioLab will become a part of supporting drug discovery and contributes to the human society."

Comment from Dai Takehara, President & CEO, PRISM BioLab Co., Ltd.

"I would like to express my heartfelt gratitude to our existing and new investors who have given us the great support. We will use the funds to increase global presence of our drug discovery platform and promote research and development to create many new drugs."

About PRISM BioLab

PRISM BioLab Co., Ltd., is a biotechnology company with proprietary small molecule drug discovery platform "PepMetics™ Technology". The PepMetics™ Molecules are designed to mimic α -helix or β -turn peptide using a unique stable scaffold with corresponding dihedral angles. These motifs are essential for protein-protein interactions within the cell, especially related to transcription and translation. Using our small molecule drug discovery technology, two clinical-stage assets for cancer and fibrosis have been developed and licensed. Many early lead molecules have also been created for novel or previously undruggable targets.